Latest News and Press Releases

Allyx Therapeutics first patient first patient has been dosed with its lead compound, ALX-001, in new Parkinson's Disease clinical study

60 Degrees Pharma begins enrolling patients for a tafenoquine babesiosis trial at Yale, Tufts, and Rhode Island Hospital, with results expected Sept., 2025

Allyx Therapeutics Announces First Alzheimer’s Disease Patient Treated with Lead Compound ALX-001.

Allyx Therapeutics Announces Positive Phase 1b Multiple Ascending Dose Data and Advances ALX-001 to Patients

Allyx Therapeutics Phase 1a Clinical Data Presented at Clinical Trials on Alzheimer's Disease Meeting Support Continued Clinical Development

Allyx Therapeutics presents Phase 1 ALX-001 data at CTAD. ALX-001 is a small molecule with unique mechanism at mGluR5 to protect and preserve synapses.

LAS VEGAS, Nov. 09, 2021 (GLOBE NEWSWIRE) -- The Las Vegas trial between health insurance giant United and TeamHealth Nevada emergency room clinicians entered its third week yesterday, with Judge...

~ Financing Co-led by OrbiMed and Logos Capital to Support Advancement of Proprietary Gene Monoclonal Antibody Platform (GMAB) ~ ~ Stephen Squinto, Ph.D., Appointed Chief Executive Officer and...

TÜBINGEN, Germany and BOSTON, Aug. 13, 2019 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, announced today it has entered...

NEW YORK, May 19, 2017 (GLOBE NEWSWIRE) -- Dr. Si-Hoi Lam, Assistant Clinical Professor at Yale University School of Medicine, has been selected to join the Education Board at the American Health...